Desmoid Tumor Clinical Trial
Official title:
A Phase II Study of Sulindac and Tamoxifen in Patients With Desmoid Tumors That Are Recurrent or Not Amenable to Standard Therapy
This phase II trial is studying how well giving sulindac together with tamoxifen works in treating patients with desmoid tumor. Sulindac may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Hormone therapy using tamoxifen may fight cancer by blocking the use of estrogen. Combining sulindac with tamoxifen may kill more cancer cells.
PRIMARY OBJECTIVES:
I. To estimate the safety and efficacy of sulindac and tamoxifen in patients with recurrent
desmoid tumor (DT) and primary DT that is not readily amenable to surgery or radiation
therapy.
SECONDARY OBJECTIVES:
I. Determine the tumor response rate in patients treated with this regimen.
II. Correlate changes in Magnetic Resonance Imaging (MRI) signal features of the tumor with
clinical outcome in patients treated with this regimen.
III. Correlate pathological studies of cyclooxygenase-2 (COX-2) and estrogen/progesterone
receptor expression in the tumor with clinical outcome in patients treated with this regimen.
IV. Collect information about clinical factors that make a tumor unresectable at diagnosis
and resectable during the four courses of study treatment.
V. Determine whether short-term endocrine toxicity is associated with treatment with this
regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral sulindac and oral tamoxifen twice daily for up to 12 months (four
3-month courses) in the absence of disease progression or unacceptable toxicity. Patients who
achieve a complete response (CR) receive 1 additional month of treatment beyond documentation
of CR.
After completion of study treatment, patients are followed for 5 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561036 -
A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor
|
Phase 3 | |
Completed |
NCT00287846 -
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT06258421 -
Burden of Disease and Living Situation in Desmoid Patients
|
||
Completed |
NCT00030680 -
Radiation Therapy in Treating Patients With Aggressive Fibromatoses
|
Phase 2 | |
Recruiting |
NCT06081400 -
Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
|
N/A | |
Active, not recruiting |
NCT04871282 -
A Study of AL102 in Patients With Progressing Desmoid Tumors
|
Phase 2/Phase 3 | |
Recruiting |
NCT01567046 -
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
|
N/A | |
Completed |
NCT01137916 -
Study to Evaluate Imatinib in Desmoid Tumors
|
Phase 2 | |
Completed |
NCT00002595 -
Toremifene in Treating Patients With Desmoid Tumors
|
Phase 2 | |
Completed |
NCT03459469 -
Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059
|
Phase 1 | |
Completed |
NCT06195085 -
CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
|
||
Completed |
NCT01286662 -
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
|
N/A | |
Completed |
NCT01265030 -
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
|
Phase 1/Phase 2 | |
Completed |
NCT04289077 -
Quality of Life of Patients With Desmoid-type Fibromatosis
|
||
Completed |
NCT03190174 -
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00003019 -
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
|
Phase 2 | |
Recruiting |
NCT05949099 -
Study of Cryoablation and Nirogacestat for Desmoid Tumor
|
Phase 2 | |
Active, not recruiting |
NCT02076906 -
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
|
Phase 1 | |
Completed |
NCT00474994 -
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
|
Phase 2 | |
Active, not recruiting |
NCT03785964 -
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
|
Phase 3 |